UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 22,961 Shares of Innoviva, Inc. (NASDAQ:INVA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Innoviva, Inc. (NASDAQ:INVA) by 14.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,449 shares of the biotechnology company’s stock after selling 22,961 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.21% of Innoviva worth $2,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. US Bancorp DE boosted its stake in shares of Innoviva by 24.5% in the 3rd quarter. US Bancorp DE now owns 2,875 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 566 shares in the last quarter. GAMMA Investing LLC increased its holdings in Innoviva by 18.5% during the 3rd quarter. GAMMA Investing LLC now owns 4,119 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 643 shares during the period. FMR LLC raised its position in Innoviva by 8.2% during the 3rd quarter. FMR LLC now owns 10,119 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 771 shares during the last quarter. SummerHaven Investment Management LLC lifted its holdings in Innoviva by 1.7% in the 2nd quarter. SummerHaven Investment Management LLC now owns 59,853 shares of the biotechnology company’s stock worth $982,000 after buying an additional 980 shares during the period. Finally, Evergreen Capital Management LLC grew its position in shares of Innoviva by 10.9% in the 2nd quarter. Evergreen Capital Management LLC now owns 12,321 shares of the biotechnology company’s stock worth $202,000 after buying an additional 1,209 shares during the last quarter. 99.12% of the stock is currently owned by institutional investors.

Innoviva Price Performance

INVA opened at $18.58 on Friday. The stock’s 50 day moving average price is $19.47 and its 200-day moving average price is $18.43. Innoviva, Inc. has a 52-week low of $14.32 and a 52-week high of $21.28. The stock has a market capitalization of $1.16 billion, a PE ratio of 26.93 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.25). Innoviva had a net margin of 18.31% and a return on equity of 20.84%. The company had revenue of $89.51 million for the quarter. On average, equities research analysts predict that Innoviva, Inc. will post 0.33 EPS for the current year.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.